Companies in the Health Care sector

XLV stock price: $92.00 0.14% At close on Sep 20th, 2019

Health Care sector definition

The healthcare sector consists of companies that provide medical services, manufacture medical equipment or drugs, provide medical insurance, or otherwise facilitate the provision of healthcare to patients.

Health Care sector is composed of 853 companies with a total market capitalization of $4.95 tn

Health Care companies

Aetna Inc. (AET)

Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions.The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products, including pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. has a collaborative agreement with Community Care Physician Network, LLC to deliver healthcare services in North Carolina. The company was founded in 1853 and is based in Hartford, Connecticut.

  • Industry: Medical Specialities
  • Country: USA
  • Market cap: $66.38 bn
  • 3M gains: +6.47 %
  • Avg. Volume: 12.4 M

Medtronic plc (MDT)

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide.The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions. The company's Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company's Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $122.53 bn
  • 3M gains: +12.48 %
  • Avg. Volume: 22.0 M

Amgen Inc. (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar\u002FMimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $118.96 bn
  • 3M gains: +6.00 %
  • Avg. Volume: 15.1 M

Array BioPharma Inc. (ARRY)

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib\u002FGDC-0068 for the treatment of cancer, as well as ASC08\u002FDanoprevir to treat hepatitis C virus. Its drug candidates in Phase II\u002Fregistration trials comprise Larotrectinib\u002FLOXO-101, a PanTrk inhibitor for cancer; Tucatinib\u002FONT-380, a HER2 inhibitor for breast cancer; and Varlitinib\u002FASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A\u002FC-related dilated cardiomyopathy; Motolimod\u002FVTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib\u002FLY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I\u002FII clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $4.81 bn
  • 3M gains: +106.52 %
  • Avg. Volume: 29.0 M

Astrazeneca PLC (AZN)

AstraZeneca PLC develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.Its marketed products comprise Arimidex, Casodex\u002FCosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1\u002FAtacand HCT\u002FAtacand Plus, Brilinta\u002FBrilique, Crestor, Imdur, Plendil, Seloken\u002FToprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga\u002FForxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp\u002FDaxas, Duaklir Genuair, Eklira Genuair\u002FTudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler\u002FPulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra\u002FFluMist Quadrivalent and Synagis for infection diseases; Movantik\u002FMoventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec\u002FPrilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. It has collaboration agreements with Valeant Holdings Ireland, Eli Lilly and Company, FibroGen, Astellas, Pieris Pharmaceuticals Inc, Champions Oncology, Inc., Moderna Therapeutics, Takeda Pharmaceutical Company Limited, and Chembio Diagnostics, Inc.; definitive agreement with Foundation Medicine, Inc.; a clinical trial collaboration agreement with G1 Therapeutics, Inc.; collaboration and license agreement with Celgene International Sàrl; and a license agreement with LEO Pharma A\u002FS. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

  • Industry: Major Pharmaceuticals
  • Country: United Kingdom
  • Market cap: $101.32 bn
  • 3M gains: +10.36 %
  • Avg. Volume: 15.5 M

Baxter International Inc. (BAX)

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments.It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $38.55 bn
  • 3M gains: +6.33 %
  • Avg. Volume: 11.3 M

Boston Scientific Corporation (BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $55.24 bn
  • 3M gains: +3.84 %
  • Avg. Volume: 27.0 M

GlaxoSmithKline PLC (GSK)

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide.It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc has a strategic drug discovery collaboration with Exscientia Limited to discover novel and selective small molecules for up to 10 disease-related targets across various therapeutic areas; and a collaboration agreement with Oklahoma Medical Research Foundation for the discovery, development, and commercialization of therapies to prevent organ damage and death caused by acute pancreatitis, lung injury, and trauma conditions. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

  • Industry: Major Pharmaceuticals
  • Country: United Kingdom
  • Market cap: $101.43 bn
  • 3M gains: +4.57 %
  • Avg. Volume: 11.1 M

Merck & Company, Inc. (MRK)

Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances.The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Aduro Biotech, Inc.; Premier Inc.; Cancer Research Technology; Corning; Pfizer Inc.; AstraZeneca PLC.; SELLAS Life Sciences Group Ltd.; and Aeglea BioTherapeutics, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $205.27 bn
  • 3M gains: +1.38 %
  • Avg. Volume: 47.1 M

NxStage Medical, Inc. (NXTM)

NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure.Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $1.95 bn
  • 3M gains: +6.23 %
  • Avg. Volume: 4.3 M

Stellar Biotechnologies, Inc. (SBOT)

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia.The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $6.02 M
  • 3M gains: +25,921,500.00 %
  • Avg. Volume: 4.7 M

Abbott Laboratories (ABT)

  • Industry: Major Pharmaceuticals
  • Country:
  • Market cap: $129.92 bn
  • 3M gains: -1.30 %
  • Avg. Volume: 23.7 M

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide.It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic\u002Fmonitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $65.79 bn
  • 3M gains: +2.85 %
  • Avg. Volume: 4.9 M

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally.The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

  • Industry: Medical Specialities
  • Country: USA
  • Market cap: $11.63 bn
  • 3M gains: +6.61 %
  • Avg. Volume: 4.4 M

Endocyte, Inc. (ECYT)

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $1.29 bn
  • 3M gains: +36.85 %
  • Avg. Volume: 13.6 M

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally.It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

  • Industry: Industrial Specialties
  • Country: USA
  • Market cap: $36.82 bn
  • 3M gains: +13.68 %
  • Avg. Volume: 5.9 M

Hologic, Inc. (HOLX)

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally.The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture\u002Fnucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

  • Industry: Medical Electronics
  • Country: USA
  • Market cap: $13.18 bn
  • 3M gains: +1.79 %
  • Avg. Volume: 8.1 M

Insys Therapeutics, Inc. (INSY)

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $355 M
  • 3M gains: +1,424,220,000.00 %
  • Avg. Volume: 17.8 M

IQVIA Holdings, Inc. (IQV)

IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific.It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $27.95 bn
  • 3M gains: -1.93 %
  • Avg. Volume: 6.3 M

Johnson & Johnson (JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide.Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $360.22 bn
  • 3M gains: -6.65 %
  • Avg. Volume: 35.5 M

Health Care sector performance

Healthcare sector ETF shares gained 0.54% this week, ending at $92.00. This week was the 4th green week in a row.

XLV marked an uptrend of rising tops and rising bottoms. Since its last top early July at $94.42, price slid and bounced up back from $88.19. Breaking down under $88.19 would cancel the current uptrend and it might test lower supports. Note that $94.42 might act as a resistance line. Since price and SMA40w lines crossed up late August, XLV climbed $3.24 (3.65%). Since SMA20d and SMA40w crossed up late May, XLV price climbed $2.82 per share (3.16%). Far behind is the all-time high Healthcare sector ETF recorded early October but price is just -3.03% below that top.

Healthcare sector ETF performance
3 months-1.85 %
6 months+1.95 %
1 year-1.18 %

Health Care sector industries

Industry
Biotechnology
Hospital/Nursing Management
Industrial Specialties
Major Pharmaceuticals
Medical Electronics
Medical Specialities
Medical/Dental Instruments
Medical/Nursing Services
Ophthalmic Goods
Other Pharmaceuticals
Precision Instruments

Top performing stocks in the Health Care sector

Company3M gain6M gain
Aetna+6.47 %+21.07 %
Medtronic+12.48 %+23.67 %
Amgen+6.00 %+7.15 %
Array+106.52 %+149.22 %